1182 related articles for article (PubMed ID: 22314934)
21. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
[TBL] [Abstract][Full Text] [Related]
22. Plumbagin restrains hepatocellular carcinoma angiogenesis by suppressing the migration and invasion of tumor-derived vascular endothelial cells.
Wei Y; Yang Q; Zhang Y; Zhao T; Liu X; Zhong J; Ma J; Chen Y; Zhao C; Li J
Oncotarget; 2017 Feb; 8(9):15230-15241. PubMed ID: 28122355
[TBL] [Abstract][Full Text] [Related]
23. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS
Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
[TBL] [Abstract][Full Text] [Related]
25. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
Harmon CS; DePrimo SE; Raymond E; Cheng AL; Boucher E; Douillard JY; Lim HY; Kim JS; Lechuga MJ; Lanzalone S; Lin X; Faivre S
J Transl Med; 2011 Jul; 9():120. PubMed ID: 21787417
[TBL] [Abstract][Full Text] [Related]
26. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
27. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.
Shi L; Yang F; Luo F; Liu Y; Zhang F; Zou M; Liu Q
Tumour Biol; 2016 Sep; 37(9):12791-12803. PubMed ID: 27449032
[TBL] [Abstract][Full Text] [Related]
28. The epigallocatechin gallate derivative Y
Liao ZH; Zhu HQ; Chen YY; Chen RL; Fu LX; Li L; Zhou H; Zhou JL; Liang G
J Ethnopharmacol; 2020 Sep; 259():112852. PubMed ID: 32278759
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
30. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
Zhong L; Fu XY; Zou C; Yang LL; Zhou S; Yang J; Tang Y; Cheng C; Li LL; Xiang R; Chen LJ; Chen YZ; Wei YQ; Yang SY
Int J Cancer; 2014 Dec; 135(12):2972-83. PubMed ID: 24789676
[TBL] [Abstract][Full Text] [Related]
31. Determinants for in vivo antitumor effect of angiogenesis inhibitor SU5416 formulated in PEGylated emulsion.
Ogawara K; Abe S; Un K; Yoshizawa Y; Kimura T; Higaki K
J Pharm Sci; 2014 Aug; 103(8):2464-9. PubMed ID: 24985750
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma.
Esposito V; Palescandolo E; Spugnini EP; Montesarchio V; De Luca A; Cardillo I; Cortese G; Baldi A; Chirianni A
Clin Cancer Res; 2006 Apr; 12(8):2634-9. PubMed ID: 16638877
[TBL] [Abstract][Full Text] [Related]
33. Small molecule R1498 as a well-tolerated and orally active kinase inhibitor for hepatocellular carcinoma and gastric cancer treatment via targeting angiogenesis and mitosis pathways.
Zhang C; Wu X; Zhang M; Zhu L; Zhao R; Xu D; Lin Z; Liang C; Chen T; Chen L; Ren Y; Zhang J; Qin N; Zhang X
PLoS One; 2013; 8(6):e65264. PubMed ID: 23755206
[TBL] [Abstract][Full Text] [Related]
34. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.
Huynh H; Chow PK; Tai WM; Choo SP; Chung AY; Ong HS; Soo KC; Ong R; Linnartz R; Shi MM
J Hepatol; 2012 Mar; 56(3):595-601. PubMed ID: 22027573
[TBL] [Abstract][Full Text] [Related]
35. Suppression of vascular endothelial growth factor via inactivation of eukaryotic elongation factor 2 by alkaloids in Coptidis rhizome in hepatocellular carcinoma.
Tan HY; Wang N; Tsao SW; Zhang Z; Feng Y
Integr Cancer Ther; 2014 Sep; 13(5):425-34. PubMed ID: 24363282
[TBL] [Abstract][Full Text] [Related]
36. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
[TBL] [Abstract][Full Text] [Related]
37. Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.
Jung KH; Zheng HM; Jeong Y; Choi MJ; Lee H; Hong SW; Lee HS; Son MK; Lee S; Hong S; Hong SS
Cancer Lett; 2013 Jan; 328(1):176-87. PubMed ID: 22902995
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
39. Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model.
Tanaka Y; Shibata MA; Morimoto J; Otsuki Y
Anticancer Res; 2011 Apr; 31(4):1225-34. PubMed ID: 21508369
[TBL] [Abstract][Full Text] [Related]
40. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
